查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1771589

Vifugart（Efgartigimod）市場規模、佔有率、趨勢分析報告：按適應症、給藥途徑、地區、細分市場預測，2025-2030 年

Vyvgart (Efgartigimod) Market Size, Share & Trends Analysis Report By Indication (Generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)), By Route of Administration, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

Wifgart（Efgartigimod）市場的成長與趨勢：

根據 Grand View Research, Inc. 的最新報告，全球 Vifugart（efgaltigimod）市場規模預計到 2030 年將達到 55 億美元，2025 年至 2030 年的複合年成長率為 13.6%。

efgartigimod 是由 argenx SE 開發的First-in-Class新生兒 Fc 受體 (FcRn) 拮抗劑，隨著其治療領域在多種自體免疫疾病中的擴展，其市場正在快速發展。 efgartigimod 最初核准用於治療重症肌無力 (gMG)，隨後又核准用於治療原發性血小板減少性疾病(ITP) 和慢性脫髓鞘多發性神經炎(CIDP)，目前正在進一步開發用於治療 FcRn 相關的免疫疾病。

Wifgart 的臨床價值在於其獨特的作用機制，透過抑制 FcRn 循環途徑來降低致病性 IgG 自體抗體。這種標靶療法可以選擇性地調節免疫功能，而不會廣泛抑制免疫系統，並且安全性良好。該療法已在慢性抗體依賴性疾病（例如 gMG 和 CIDP）中顯示出強大的療效，並且越來越多的證據支持其在其他自體免疫疾病中的應用。

儘管成人患者仍然是最大的治療人群，尤其是在治療諸如鉅細胞病毒性肌炎（gMG）等已確定的適應症方面，但兒童患者的治療潛力日益成長，尤其是在慢性自體免疫神經病變和血液系統疾病方面。對年輕患者進行早期療育，可能透過減緩病情進展和減少對廣譜免疫抑制劑的依賴，帶來長期益處。

專業藥局在Wifgart的經銷模式中佔據核心地位，尤其對於需要精準協調和病患支援的輸液和皮下製劑而言。醫院藥局在管理誘導用藥和複雜病例方面仍然是至關重要的合作夥伴，尤其對於新診斷和嚴重患者而言。專業銷售管道透過個人化照護方案、輸液計畫和遠端患者協助，持續提升患者的可近性和依從性。

2025年4月，FDA核准了Hyfudura的預填充式注射器製劑，用於gMG和CIDP患者皮下注射自我給藥，可在30秒內完成皮下給藥，顯著提高治療靈活性和依從性。

此外，2025年4月，EMA人用藥品委員會（CHMP）發表了積極意見，建議核准VYVGART皮下注射劑在歐洲用於治療CIDP，為該地區30多年來首個CIDP標靶治療的核准奠定了基礎。

2024年11月，繼ADHERE試驗取得正面結果後，Hyfudura複合皮下注射液在中國核准用於治療CIDP，進一步擴大了Argenx的全球影響力，鞏固了其在神經肌肉市場的地位。

隨著全球需求的成長，確保產品供應仍是 Argenx 的策略重點。對供應鏈擴充性和以患者為中心的數位平台的投資增強了護理的連續性，從而增強了醫療服務提供者和患者的權能。這些工具對於長期復發性自體免疫疾病的管理尤其重要，因為護理的無縫過渡和主動的疾病監測對療效有重大影響。

Wifcart 的成功凸顯了向精準免疫療法的模式轉移，這種療法可以調節特定的疾病通路，並產生持久的標靶效應。隨著我們對自體免疫疾病的認知和診斷能力不斷提高，Wifcart 仍然是 FcRn 抑制劑領域的領先選擇，有望帶來更佳的療效，並重塑一系列免疫介導疾病的治療標準。

Wifgart（Efgartigimod）市場報告重點

  • 從適應症來看，重症肌無力 (gMG) 仍將是 2024 年 Vifugart (efgartigimod) 市場的主要適應症，由於該藥物血清陽性患者比例高，且透過 FcRn 抑制標靶作用機制，其將佔據最大市場佔有率。其優異的臨床表現、良好的安全性以及最新的治療指南正在加速其在主要市場的推廣。
  • 根據給藥途徑，靜脈輸液將在 2024 年佔據給藥途徑領域的主導地位。然而，皮下製劑正在迅速轉變，尤其是最近核准的預填充式注射器，這種注射器允許自我給藥並為患者提供更大的便利。
  • 受自體免疫疾病高診斷率和治療率、優惠的報銷政策以及強大的專業藥房基礎設施的推動，北美在 2024 年引領了 WiFgart 市場。該地區也受益於活性化和創新免疫療法的早期採用。
  • Algenx SE 繼續引領全球 Vifugart (efgaltigimod) 市場，憑藉其強大的研發開發平臺、不斷成長的國際核准以及與中國再鼎醫藥等區域性企業的戰略夥伴關係。公司專注於供應鏈彈性、患者援助項目和基於平台的開發，這將支持其在多個適應症和地區的長期成長。

目錄

第1章調查方法與範圍

第2章執行摘要

第 3 章 Wifgart（Efgartigimod）市場的變數、趨勢與範圍

  • 市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
  • 管道分析
  • 專利到期分析
  • 定價分析

第4章 VIFGART（EFGARTIGIMOD）市場：適應症業務分析

  • 2024年及2030年指示市場佔有率
  • 指示細分儀表板
  • 市場規模、預測與趨勢分析（2018-2030 年）
  • 慢性脫髓鞘多發性神經炎（CIDP）
  • 全身性重症肌無力（gMG）
  • 其他

第5章 VIFGART（EFGARTIGIMOD）市場路線管理業務分析

  • 2024 年及 2030 年給藥途徑市場佔有率
  • 給藥途徑細分儀表板
  • 按管理路線分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 靜脈輸液
  • 皮下注射
  • 預填充式注射器

第6章 Wifgart（Efgartigimod）市場：區域估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018年至2030年市場規模與預測趨勢分析：
  • 北美洲
    • 2018-2030年各國情況
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Argenx SE

第 8 章 結論

Product Code: GVR-4-68040-618-7

Vyvgart (Efgartigimod) Market Growth & Trends:

The global Vyvgart (Efgartigimod) market size is anticipated to reach USD 5.50 billion by 2030 and is projected to grow at a CAGR of 13.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market for Vyvgart (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) antagonist developed by argenx SE, is rapidly evolving as its therapeutic footprint expands across multiple autoimmune indications. Initially approved for generalized myasthenia gravis (gMG), Vyvgart has since entered the treatment landscapes for Primary Immune Thrombocytopenia (ITP) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with ongoing exploration into additional FcRn-related immune disorders.

Vyvgart's clinical value lies in its unique mechanism of action that reduces pathogenic IgG autoantibodies by inhibiting the FcRn recycling pathway. This targeted approach allows for selective immunomodulation without broadly suppressing the immune system, offering a favorable safety profile. The treatment has demonstrated robust efficacy in chronic, antibody-driven conditions like gMG and CIDP, with growing evidence supporting its use across other autoimmune indications.

While adult patients represent the largest treated population, especially in well-established indications such as gMG, the therapeutic potential for pediatric use is gaining momentum, particularly in chronic autoimmune neuropathies and hematologic disorders. Early intervention in younger patients could offer long-term benefits by curbing disease progression and reducing reliance on broad-spectrum immunosuppressants.

Specialty pharmacies are at the forefront of Vyvgart's distribution model, particularly due to the drug's infusion-based and subcutaneous formulations, which require precise coordination and patient support. Hospital pharmacies continue to be key partners in managing induction and complex cases, especially for newly diagnosed or severely affected patients. Increasingly, specialty distribution channels are enhancing access and adherence through personalized care programs, infusion scheduling, and remote patient engagement.

In April 2025, the FDA approved a prefilled syringe formulation of VYVGART Hytrulo for self-administration in patients with gMG and CIDP. This enables subcutaneous delivery in under 30 seconds, significantly improving treatment flexibility and adherence.

Also in April 2025, the EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of VYVGART subcutaneous injection for CIDP in Europe, setting the stage for the first targeted CIDP therapy approval in the region in over three decades.

In November 2024, VYVGART Hytrulo received regulatory approval in China for treating CIDP, following strong results from the ADHERE trial. This further expanded its global footprint and solidified Argenx's position in neuromuscular markets.

As demand grows globally, ensuring consistent product availability remains a strategic priority for argenx. Investments in supply chain scalability and patient-centered digital platforms are reinforcing treatment continuity and empowering both providers and patients. These tools are especially critical in managing long-term, relapsing autoimmune conditions, where seamless care transitions and proactive disease monitoring can significantly impact outcomes.

The success of Vyvgart underscores a broader paradigm shift toward precision immunotherapies that modulate specific disease pathways with durable, targeted effects. As awareness and diagnostic capabilities for autoimmune diseases continue to improve, Vyvgart is poised to remain a leading option in the FcRn inhibition class, driving better outcomes and reshaping the standard of care across a range of debilitating immune-mediated disorders.

Vyvgart (Efgartigimod) Market Report Highlights:

  • Based on indication, Generalized Myasthenia Gravis (gMG) remained the leading indication in the Vyvgart (Efgartigimod) market in 2024, accounting for the largest share due to the high prevalence of antibody-positive patients and the drug's targeted mechanism of action through FcRn inhibition. Strong clinical outcomes, favorable safety profile, and updates to treatment guidelines have accelerated adoption across major markets.
  • Based on route of administration, Intravenous (IV) Infusion dominated the route of administration segment in 2024, primarily due to its early commercial availability and widespread adoption in hospital settings for induction therapy. However, the market is witnessing a rapid shift towards subcutaneous formulations, particularly the recently approved prefilled syringe, which offers self-administration and greater patient convenience.
  • North America led the Vyvgart market in 2024, supported by high diagnosis and treatment rates of autoimmune diseases, favorable reimbursement policies, and a robust specialty pharmacy infrastructure. The region also benefits from increasing clinical trial activity and early adoption of innovative immunotherapies.
  • Argenx SE continued to lead the Vyvgart (Efgartigimod) market globally, leveraging its robust R&D pipeline, expanding international approvals, and strategic partnerships with regional players like Zai Lab in China. The company's focus on supply chain resilience, patient assistance programs, and platform-based development supports its long-term growth across multiple indications and geographies.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Vyvgart (Efgartigimod) Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
  • 3.4. Pipeline Analysis
  • 3.5. Patent Expiry Analysis
  • 3.6. Pricing Analysis

Chapter 4. Vyvgart (Efgartigimod) Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2024 & 2030
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 4.4. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    • 4.4.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, 2018 - 2030 (USD Million)
  • 4.5. Generalized Myasthenia Gravis (gMG)
    • 4.5.1. Generalized Myasthenia Gravis (gMG) Market, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Vyvgart (Efgartigimod) Market: Route of Administration Business Analysis

  • 5.1. Route of Administration Market Share, 2024 & 2030
  • 5.2. Route of Administration Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 5.4. Intravenous (IV) Infusion
    • 5.4.1. Intravenous (IV) Infusion Market, 2018 - 2030 (USD Million)
  • 5.5. Subcutaneous (SC) Injection
    • 5.5.1. Subcutaneous (SC) Injection Market, 2018 - 2030 (USD Million)
  • 5.6. Prefilled Syringes
    • 5.6.1. Prefilled Syringe Market, 2018 - 2030 (USD Million)

Chapter 6. Vyvgart (Efgartigimod) Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Argenx SE
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives

Chapter 8. Conclusion

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global Vyvgart (Efgartigimod) market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 5. Global Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 6. North America Vyvgart (Efgartigimod) market, by country, 2018 - 2030 (USD Million)
  • Table 7. North America Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 8. North America Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 9. U.S. Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 10. U.S. Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 11. Canada Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 12. Canada Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 13. Mexico Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 14. Mexico Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 15. Europe Vyvgart (Efgartigimod) market, by country, 2018 - 2030 (USD Million)
  • Table 16. Europe Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 17. Europe Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18. UK Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 19. UK Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 20. Germany Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 21. Germany Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 22. France Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 23. France Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24. Italy Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 25. Italy Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 26. Spain Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 27. Spain Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 28. Norway Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 29. Norway Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 30. Denmark Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 31. Denmark Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 32. Sweden Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 33. Sweden Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 34. Asia Pacific Vyvgart (Efgartigimod) market, by country, 2018 - 2030 (USD Million)
  • Table 35. Asia Pacific Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 36. Asia Pacific Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 37. Japan Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 38. Japan Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39. China Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 40. China Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 41. India Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 42. India Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43. Australia Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 44. Australia Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 45. South Korea Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 46. South Korea Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 47. Thailand Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 48. Thailand Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 49. Latin America Vyvgart (Efgartigimod) market, by country, 2018 - 2030 (USD Million)
  • Table 50. Latin America Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 51. Latin America Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 52. Brazil Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 53. Brazil Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 54. Argentina Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 55. Argentina Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 56. Middle East & Africa Vyvgart (Efgartigimod) market, by country, 2018 - 2030 (USD Million)
  • Table 57. Middle East & Africa Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 58. Middle East & Africa Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 59. South Africa Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 60. South Africa Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 61. Saudi Arabia Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 62. Saudi Arabia Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 63. UAE Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 64. UAE Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 65. Kuwait Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 66. Kuwait Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Vyvgart (Efgartigimod) market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Indication and route of administration outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Vyvgart (Efgartigimod) market dynamics
  • Fig. 12 Vyvgart (Efgartigimod) market: Porter's five forces analysis
  • Fig. 13 Vyvgart (Efgartigimod) market: PESTLE analysis
  • Fig. 14 Indication market, 2018 - 2030 (USD Million)
  • Fig. 15 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market, 2018 - 2030 (USD Million)
  • Fig. 16 Generalized Myasthenia Gravis (gMG) market, 2018 - 2030 (USD Million)
  • Fig. 17 Others market, 2018 - 2030 (USD Million)
  • Fig. 18 Route of Administration market, 2018 - 2030 (USD Million)
  • Fig. 19 Intravenous (IV) Infusion market, 2018 - 2030 (USD Million)
  • Fig. 20 Subcutaneous (SC) Injection market, 2018 - 2030 (USD Million)
  • Fig. 21 Prefilled Syringe market, 2018 - 2030 (USD Million)
  • Fig. 22 Vyvgart (Efgartigimod) market revenue, by region
  • Fig. 23 Regional marketplace: Key takeaways
  • Fig. 24 North America Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. country dynamics
  • Fig. 26 U.S. Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 27 Canada country dynamics
  • Fig. 28 Canada Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 29 Mexico country dynamics
  • Fig. 30 Mexico Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 31 Europe Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 32 UK country dynamics
  • Fig. 33 UK Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 34 Germany country dynamics
  • Fig. 35 Germany Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 36 France country dynamics
  • Fig. 37 France Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 38 Italy country dynamics
  • Fig. 39 Italy Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 40 Spain country dynamics
  • Fig. 41 Spain Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 42 Norway country dynamics
  • Fig. 43 Norway Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 44 Sweden country dynamics
  • Fig. 45 Sweden Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 46 Denmark country dynamics
  • Fig. 47 Denmark Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 48 Asia Pacific Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 49 Japan country dynamics
  • Fig. 50 Japan Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 51 China country dynamics
  • Fig. 52 China Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 53 India country dynamics
  • Fig. 54 India Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 55 Australia country dynamics
  • Fig. 56 Australia Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 57 South Korea country dynamics
  • Fig. 58 South Korea Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 59 Thailand country dynamics
  • Fig. 60 Thailand Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 61 Latin America Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 62 Brazil country dynamics
  • Fig. 63 Brazil Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 64 Argentina country dynamics
  • Fig. 65 Argentina Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 66 MEA Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 67 South Africa country dynamics
  • Fig. 68 South Africa Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 69 Saudi Arabia country dynamics
  • Fig. 70 Saudi Arabia Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 71 UAE country dynamics
  • Fig. 72 UAE Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 73 Kuwait country dynamics
  • Fig. 74 Kuwait Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 75 Company categorization
  • Fig. 76 Company market position analysis
  • Fig. 77 Strategic framework